Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 9, 2000, Pages 1281-1284

  Hill, Michael D ^a   Barber, Philip A ^a   Takahashi, Jennifer ^a   Demchuk, Andrew M ^a   Feasby, Thomas E ^a   Buchan, Alastair M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; METHYLPREDNISOLONE; RANITIDINE;

AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; DRUG FATALITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PARTIAL THROMBOPLASTIN TIME; RISK ASSESSMENT; STROKE;

EID: 0034595403     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. 1. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. 34th ed. Ottawa: The Association; 1999. p. 31.
2. 2. Demchuk AM, Morgenstern LB, Krieger DW, Chi TL, Hu W, Wein TH, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Sroke 1999;30:34-9.
3. 3. Tsang TS, Califf RM, Stebbins AL, Lee KL, Cho S, Ross AM, et al. Incidence and impact of on outcome of streptokinase allergy in the GUSTO-1 trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. Am J Cardiol 1997;79:1232-5.
4. 4. White HD, Cross DB, Williams BF, Norris RM. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J 1990;64: 177-81.
5. 5. Purvis JA, Booth NA, Wilson CM, Aggi JAA, McClusky DR. Anaphylactoid reaction after injection of altepase. Lancet 1993;341:966-7.
6. 6. Massell D, Gill JB, Cairns JA. Anaphylactoid reaction during infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction. Can J Cardiol 1991;7:298-302.
7. 7. Francis CW, Brenner B, Leddy JP, Marder VJ. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol 1991;77:562-3.
8. 8. Marder VJ, Brenner B, Totterman S, Francis CW, Rubin R, Rao AK, et al. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med 1992;119:485-95.
9. 9. Pancioli A, Brott T, Donaldson V, Miller R. Asymmetric angioneurotic oedema associated with thrombolysis for acute stroke. Ann Emerg Med 1997; 30:227-9.
10. 10. Rudolf J, Grond M, Prince WS, Schmulling S, Heiss WD. Evidence of anaphylaxy following alteplase infusion. Stroke 1999;30:1142-3.
11. 11. Fayad PB, Albers GW, Frey JL, Raps EC. Orolingual angioedema complicating rt-PA therapy for acute ischemic stroke [abstract]. Stroke 1999;30:242.
12. 12. Felberg RA, Wein TH, Demchuk AM, Hickenbottom SL, Malkoff M, Morgenstern LB, et al. Oropharyngeal angioedema: a clinically important complication of intravenous recombinant tissue plasminogen activator [abstract]. 124th Annual Meeting of the American Neurological Association; 1999 Oct 9-13; Seattle.
13. 13. Bennett WR, Yawn DH, Migliore PJ, Young JB, Pratt CM, Raizner AE, et al. Activation of the complement system by recombinant tissue plasminogen activator.J Am Coll Cardiol 1987;10:627-32.
14. 14. Reed BR, Chen AB, Tanswell P, Prince WS, Wert RM Jr, Glaesle-Schwarz L, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost 1990;64:276-80.
15. 15. Topol EJ, Morris DC, Smalling RW, Schumacher RR, Taylor CR, Nishikawa A, et al. A multi-centre randomized placebo controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction. J Am Coll Cardiol 1987;9:1205-13.
16. 16. Cugno M, Cicardi M, Colucci M, Bisiani G, Merlini PA, Spinola A, et al. Non-neutralizing antibodies to tissue-type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost 1996;76:234-8.
17. 17. Reed BR, Chen AB, Tanswell P, Prince WS, Wert RM, Glaesle-Schwarz L, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thomb Haemost 1990;64:276-80.
18. 18. Blais C Jr, Rouleau JL, Brown NJ, Lepage Y, Spence D, Munoz C, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999;43:293-302.
19. 19. Markovic SN, Inwards DJ, Frigas EA, Phyliky RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med 2000;132:144-50.
20. 20. Van der Linden PWG, Hack E, Struyvenberg A, Roem D, Brouwer MC, de Boer JP, et al. Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock. Blood 1993;82:1740-8.
21. 21. Shimaya K, Sumi H, Maruyama M, Mihara H. A rapid and strong increase of plasminogen activator induced by experimental anaphylaxis in rabbits. Enzyme 1992;46:204-12.
22. 22. Buchan AM, Gertler SZ, Huang ZG, Li H, Chaundy KE, Xue D. Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase. Neuroscience 1994; 61:1-11.
23. 23. Zamrini EY, Meador KJ, Loring DW, Nichols FT, Lee GP, Figueroa RE, et al. Unilateral cerebral inactivation produces differential left/right heart rate responses. Neurology 1990;40:1408-11.
24. 24. Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular effects of human insular cortex stimulation. Neurology 1992;42:1727-32.
25. 25. Yoon BW, Morillo CA, Cechetto DR, Hachinski V. Cerebral hemispheric lateralization in cardiac autonomic control. Arch Neurol 1997;54:741-4.
26. 26. Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998;24:635-8.